Next steps in AAV preclinical and translational R&D

Cell & Gene Therapy Insights 2021; 7(6), 611–618


Published: 1 July 2021
Anna Tretiakova PhD, Shari Gordon

Anna Tretiakova, PhD, is a Senior Vice President of Product Development, leading the company’s research and translational programs to deliver clinical candidate vectors. Anna is an industry veteran with more than 30 years of of research and development experience that spans basic research and non-clinical translational sciences, progressing from a bench scientist in academia to senior leadership roles with biotechnology and pharmaceutical organizations. She has spent over a decade exclusively focused on AAV gene therapy for monogenic and non-monogenic diseases in various therapeutic areas at the University of Pennsylvania Gene Therapy Program, Pfizer Rare Disease Research Unit, SwanBio Therapeutics, and, most recently, at AskBio. She completed her graduate education in molecular biology and biochemistry with a PhD from Thomas Jefferson University in Philadelphia and diploma from Novosibirsk State University in Russia.

Shari Gordon is the Senior Director of Immunology at Asklepios Biopharmaceutical (Ask Bio). Shari is a viral immunologist with 18 years of experience in infectious diseases. Shari’s passion for science began with her graduate work at Emory University focused on HIV pathogenesis and continued with her post graduate work that evaluated novel vaccine approaches using viral vectors. Shari had an illustrious career at GlaxoSmithKline and then ViiV Healthcare advancing biologics for the treatment of HIV and Cancer before joining Ask Bio. At Ask Bio Shari leads the clinical immunology and immunoassays teams that characterize the immune response to AAV gene therapy and immune modulatory approaches.